CAREDX INC (CDNA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CDNA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CDNA | Independent Director | 74 | ["Professor of Medicine, Stanford School of Medicine (2000 - Present)","Chief Officer (Scientific Workforce Diversity), National Institutes of Health (2014 - 2020)","Senior Associate Dean for Diversity and Leadership, Stanford School of Medicine (2005 - 2014)","Assistant Professor of Medicine, Stanford School of Medicine (1987 - 2000)","Registrar, Hammersmith Hospitals NHS Trust","Relevant Industry Knowledge in transplant medicine","Expertise in genomic-based diagnostics for acute rejection","Experience in ESG matters","Recognized for enhancing gender and racial diversity"] | ["Governance & Nominating Committee","Technology and Innovation Committee (Chairwoman)","Compensation and Human Capital Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
Biography sourced from the proxy statement filing.
Independent Director Age: 74 Independent Director since 2021 Committees: Governance & Nominating Committee Technology and Innovation Committee (Chairwoman) Professional Experience Professor of Medicine, Stanford School of Medicine (2000 - Present) Chief Officer (Scientific Workforce Diversity), National Institutes of Health (2014 - 2020) Senior Associate Dean for Diversity and Leadership, Stanford School of Medicine (2005 - 2014) Assistant Professor of Medicine, Stanford School of Medicine (1987 - 2000) Registrar, Hammersmith Hospitals NHS Trust Key Skills & Qualifications Relevant Industry Knowledge: Dr. Valantine has more than thirty-five years of expertise in transplant medicine. She is an international leader in the development and application of genomic-based diagnostics for acute rejection, having led the first ever randomized controlled trial of gene- expression profiling published in the New England Journal of Medicine, setting the stage for FDA approval. She further advanced the field by publishing the first application of donor-derived cell-free DNA as a sensitive and specific biomarker for heart transplant rejection, an approach that has become widely adopted across all other solid organ transplants. Her pioneering work across several platforms has enabled the advancement of a multi-modality approach to molecular diagnostics services. ESG: Dr. Valantine s experience in ESG matters spans more than two decades. She is nationally recognized for her transformative approaches to enhancing both gender and racial diversity among faculty. As the inaugural Senior Associate Dean for Diversity and Leadership at Stanford University School of Medicine, and then as the inaugural NIH Chief Officer for scientific workforce diversity, she has built and disseminated successful national programs to ensure both workforce diversity and health equity across the NIH research ecosystem. Other Boards Director, BridgeBio Pharma (Nasdaq: BBIO) (2021 - Present) Director, Pacific Biosciences (Nasdaq: PACB) (2021 - Present) Current Organizations Founder & Principal, HAV Member, National Academy of Medicine Member, Stanford Cardiovascular Institute Previous Organizations President (Western State Affiliation), American Heart Association Education M.D., London University Fellowship, Stanford University M.B.B.S., London University